论文部分内容阅读
目的:研究二甲双胍联合维格列汀对初治Ⅱ型糖尿病患者血糖的控制效果及安全性。方法:选择2015年2月至2016年4月在我院进行治疗的2型糖尿病患者60名,按照治疗方法分为观察组和对照组,对照组使用二甲双胍治疗,观察组在对照组基础上联合维格列汀治疗,观察和比较两组治疗后的临床疗效,治疗前后血清白介素-6、肿瘤坏死因子、C反应蛋白、空腹血糖、糖化血红蛋白、餐后两小时血糖及血清淀粉酶及尿液淀粉酶水平的变化。结果:治疗后,观察组总有效率90%,明显高于对照组有效率66.7%,差异显著(P<0.05)。观察组治疗后的血清白介素-6、肿瘤坏死因子、C反应蛋白、空腹血糖、糖化血红蛋白、餐后两小时血糖水平均明显低于对照组[(7.63±1.12)d vs(8.68±1.30)d、(7.23±0.95)d vs(7.89±1.20)d、(11.14±1.56)d vs(12.12±1.89)d]、[(12.12±1.89)d vs(11.20±1.34)d、(6.89±0.96)d vs(8.23±1.10)d、(1.65±0.23)d vs(3.65±0.48)d](P<0.05)。治疗后,观察组的INS水平较对照组显著降低(P<0.05),且GLP-1水平较对照组明显升高显著差异(P<0.05)。结论:二甲双胍联合维格列汀可有效控制初治2型糖尿病患者的血糖水平,并提高治疗安全性。
Objective: To study the efficacy and safety of metformin combined with vildagliptin in the treatment of type 2 diabetes mellitus. Methods: Sixty patients with type 2 diabetes who were treated in our hospital from February 2015 to April 2016 were divided into observation group and control group according to the treatment method. The control group was treated with metformin. The observation group was united on the basis of the control group Vitalogliptin treatment, observed and compared the clinical efficacy of two groups after treatment, serum interleukin -6, tumor necrosis factor, C-reactive protein, fasting blood glucose, glycosylated hemoglobin, two hours postprandial blood glucose and serum amylase and urine Changes in amylase levels. Results: After treatment, the total effective rate was 90% in the observation group, which was significantly higher than 66.7% in the control group (P <0.05). The levels of serum interleukin-6, tumor necrosis factor, C-reactive protein, fasting blood glucose and glycosylated hemoglobin in the observation group after treatment were significantly lower than those in the control group [(7.63 ± 1.12) d vs (8.68 ± 1.30) d , (7.23 ± 0.95) d vs (7.89 ± 1.20) d, (11.14 ± 1.56) d vs (12.12 ± 1.89) d vs (12.12 ± 1.89) d vs (11.20 ± 1.34) d vs (6.89 ± 0.96) d vs (8.23 ± 1.10) d, (1.65 ± 0.23) d vs (3.65 ± 0.48) d] (P <0.05). After treatment, the INS level in the observation group was significantly lower than that in the control group (P <0.05), and the GLP-1 level was significantly higher than that in the control group (P <0.05). Conclusion: Metformin combined with vildagliptin can effectively control the blood glucose level in newly diagnosed type 2 diabetic patients and improve the safety of treatment.